| abstract |
A compound of formula (I) wherein W is O; X is NH; Y is CH 2 or an N-oxide thereof, or a pharmaceutically acceptable salt thereof, for the preparation of a pharmaceutical product for treating a neoplastic disease that responds to inhibition of VEGF receptor tyrosine kinase activity. The compounds of formula (I) may be used to treat, for example, a neoplastic disease such as cancer, retinopathy or age-dependent macular degradation. |